
|Articles|July 24, 2015
Cogstate Releases Online Cognitive Screening Solution for Alzheimer's Trial
This new version release optimizes patient recruitment with study-specific prescreening workflows and a delivery platform that allows for self-administered cognitive assessments on any modality including tablet-based assessments
Advertisement
Cogstate, a cognitive science and medical technology company, announced the latest version of its remote cognitive assessment solution for pre-screening participants in clinical trials, Precision Recruitment™ 2.1.
This new version release optimizes patient recruitment with study-specific prescreening workflows and a delivery platform that allows for self-administered cognitive assessments on any modality including tablet-based assessments. Other important new features include:
- Functionality allowing pre-screened participants to select an investigator site in their area, with automatic site notification for a more seamless enrolment process.
- The ability to deploy the solution in many different languages, as required for global clinical trials
Advertisement
Related to this article

In a video interview prior to the 2026 DPHARM conference, Andrea Valente, CEO of uMotif, shares what she expects to be at the center of the conversation—from building trust between patients and sites to where AI may and may not have a role in that relationship.

A platform-based approach connects AI across workflows, data and governance, helping life sciences organizations move from isolated wins to real scale.

In today's ACT Brief, we examine what genuine patient voice requires beyond buzzwords, why AI's next bottleneck is system integration not models, and how regulators across three jurisdictions are formalizing patient input requirements.

The clinical research industry talks about patient-centeredness constantly but embeds it too late, too narrowly, and without clear ownership, and the cost shows up in enrollment failures, protocol deviations, and outcomes that don't reflect what patients actually care about.

In today's ACT Brief, we examine FDA's expedited pathway for first-in-human trials, why operating model design matters more than sourcing strategy, and how early readiness signals predict trial risk.

FDA Opens Applications for Expedited IND Pilot Designed to Accelerate First-in-Human Trial Timelines
The pilot pairs drug sponsors with qualified research institutions to compress the path from drug identification to first-in-human study through rolling submission review and earlier coordination of institutional review board and site activation activities.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Lessons from Hundreds of Clinical Trials: AI’s Successes, Gaps, and Opportunities
2
Benchmarking Study Finds Clinical Trial Performance Is Shaped by Operating Model Design, Not Sourcing Strategy
3
DPHARM 2026: What the Patient-Site Relationship Needs Most Right Now
4
Successful IND-Enabling Programs: Everything You Need to Know
5


